Edition:
India

Menlo Therapeutics Inc (MNLO.OQ)

MNLO.OQ on NASDAQ Stock Exchange Global Select Market

4.51USD
23 Aug 2019
Change (% chg)

$-0.22 (-4.65%)
Prev Close
$4.73
Open
$4.66
Day's High
$4.82
Day's Low
$4.51
Volume
38,627
Avg. Vol
19,629
52-wk High
$11.99
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Menlo Therapeutics Reports Qtrly Net Loss Per Share $0.81
Friday, 3 May 2019 

May 2 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.COLLABORATION AND LICENSE REVENUE WAS ZERO FOR Q1 2019 VERSUS $0.5 MILLION FOR SAME PERIOD IN 2018.QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS, BASIC AND DILUTED $0.81.Q1 EARNINGS PER SHARE VIEW $-0.81, REVENUE VIEW $0.00 -- REFINITIV IBES DATA.  Full Article

Menlo Therapeutics' Serlopitant Phase 2 Clinical Trial Meets Primary Endpoint
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS’ SUCCESSFUL PHASE 2 CLINICAL TRIAL OF SERLOPITANT DEMONSTRATES REDUCTION OF PRURITUS ASSOCIATED WITH PSORIASIS.MENLO THERAPEUTICS INC - TRIAL SUCCESSFULLY MET ITS PRIMARY ENDPOINT.MENLO THERAPEUTICS - TRIAL SHOWING A STATISTICALLY SIGNIFICANT REDUCTION IN PRURITUS BASED UPON A 4-POINT IMPROVEMENT RESPONDER ANALYSIS.MENLO THERAPEUTICS INC - TRIAL ALSO PROSPECTIVELY DEFINED THREE KEY SECONDARY ENDPOINTS FOR SEQUENTIAL STEP-DOWN ANALYSES AT WEEK 4 AND DAYS 7 AND 3.MENLO THERAPEUTICS INC - SERLOPITANT WAS WELL-TOLERATED IN PHASE 2 CLINICAL TRIAL.MENLO THERAPEUTICS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED FOR SERLOPITANT TREATED PATIENTS.MENLO THERAPEUTICS INC - PLAN TO HAVE AN END OF PHASE 2 MEETING WITH FDA ABOUT SERLOPITANT IN FIRST HALF OF 2019.MENLO THERAPEUTICS INC - EXPECTS TO ENROLL FIRST PATIENT IN PHASE 2 TRIAL IN DECEMBER 2018 OR JANUARY 2019.MENLO THERAPEUTICS INC - TO BEGIN PHASE 3 PROGRAM FOR PRURITUS ASSOCIATED WITH PSORIASIS IN 2019.  Full Article

Menlo Therapeutics Begins European Prurigo Nodularis Phase 3 Trial
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS BEGINS EUROPEAN PRURIGO NODULARIS PHASE 3 TRIAL AND PRESENTS ADDITIONAL DATA FROM PN PHASE 2 TRIAL AT EADV.MENLO THERAPEUTICS INC - HAS INITIATED ENROLLMENT IN SECOND OF TWO PHASE 3 TRIALS OF SERLOPITANT FOR TREATMENT OF PRURITUS WITH PRURIGO NODULARIS.MENLO THERAPEUTICS - RESULTS FROM BOTH TRIALS ARE EXPECTED IN FIRST HALF OF 2020.  Full Article

Menlo Therapeutics Reports Q4 Loss Of $1.80 Per Share
Thursday, 29 Mar 2018 

March 28 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.MENLO THERAPEUTICS INC QUARTERLY LOSS PER SHARE $1.80.MENLO THERAPEUTICS INC QUARTERLY COLLABORATION AND LICENSE REVENUE $2.8 MILLION VERSUS $450,000.  Full Article

Novo Holdings Reports 5.05 Pct Passive Stake In Menlo Therapeutics
Friday, 9 Feb 2018 

Feb 8 (Reuters) - Menlo Therapeutics Inc ::NOVO HOLDINGS A/S REPORTS 5.05 PERCENT PASSIVE STAKE IN MENLO THERAPEUTICS INC, AS OF JANUARY 29, 2018 - SEC FILING‍​.  Full Article